Kamada Ltd (KMDA)

$7.15 +0.27 (3.92%)
Market Cap 395.63M
Revenue (ttm) 160.95M
Net Income (ttm) 14.46M
EPS (ttm) N/A
PE Ratio 23.93
Forward PE 22.94
Profit Margin 8.98%
Debt to Equity Ratio 0.04
Volume 90,000
Avg Vol 84,942
Day's Range N/A - N/A
Shares Out 57.51M
Stochastic %K 91%
Beta 0.94
Analysts Strong Sell
Price Target $14.17

Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophyla...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 8 940 6472
Fax: 972 8 940 6473
Address:
2 Holzman Street, Science Park PO Box 4081, Rehovot, Israel
benzinga
benzinga Jun. 10 at 5:10 PM
Kamada Q1 Results: Double-Digit Growth, Company Reiterates Guidance As It Hits Multiple Milestones Including Plasma Business Expansion $KMDA https://www.benzinga.com/partner/earnings/25/06/45857873/kamada-q1-results-double-digit-growth-company-reiterates-guidance-as-it-hits-multiple-milestones
0 · Reply
benzinga
benzinga Jun. 5 at 6:37 PM
Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM $KMDA https://www.benzinga.com/partner/biotech/25/06/45790529/kamada-wants-to-do-more-for-organ-transplant-patients-increases-efforts-to-build-awareness-of-its
0 · Reply
Greenpa
Greenpa Jun. 1 at 2:03 AM
$KMDA Sold out of modest KMDA position. Hope to buy back later after analyst shave future earnings estimates to reflect that will be bear about 20 to 25 percent tax hit as NOLs used up. Next year’s eps seem likely to therefore be flat to down. Hope to buy back at $6 or less if works out as seems reasonable to expect.
1 · Reply
Greenpa
Greenpa May. 20 at 11:12 AM
$KMDA Current numbers do not reflect taxes. Quote fromQ1 call transcript: But as of now, we have yet -- we're still using NOLs, so we're not paying taxes. We expect to be in a taxable income and start paying taxes at the end of 2025 or beginning of 2026.
0 · Reply
Greenpa
Greenpa May. 16 at 9:15 PM
$KMDA The plasma centers only generate 10 to 15 percent gross margins. Not what I had anticipated. Out after earning maybe a few pennies.
0 · Reply
JarvisFlow
JarvisFlow May. 15 at 2:40 PM
Benchmark updates rating for Kamada ( $KMDA ) to Buy, target set at 15.
0 · Reply
Estimize
Estimize May. 15 at 10:00 AM
Wall St is expecting 0.08 EPS for $KMDA Q2 [Reporting 08/13 BMO] http://www.estimize.com/intro/kmda?chart=historical&metric_name=eps&utm_co
0 · Reply
Estimize
Estimize May. 14 at 10:18 PM
$KMDA reported 0.07 EPS and 44.02 revenue for Q1. http://www.estimize.com/intro/kmda?chart=historical&metric_name=eps&utm_content=KMDA&utm_
0 · Reply
Abcl2028
Abcl2028 May. 14 at 7:03 PM
$KMDA when are earnings released
0 · Reply
Sidoti
Sidoti May. 8 at 7:31 PM
New research today on @kamada $KMDA #sidotiresearch Read Note: https://buff.ly/IiU11i8 #investing #smallcap #microcap
0 · Reply
Latest News on KMDA
Kamada Ltd. (KMDA) Q1 2025 Earnings Call Transcript

May 14, 2025, 1:48 PM EDT - 4 weeks ago

Kamada Ltd. (KMDA) Q1 2025 Earnings Call Transcript

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

May 14, 2025, 7:00 AM EDT - 4 weeks ago

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

Mar 19, 2025, 7:00 AM EDT - 3 months ago

Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

Kamada Ltd. (KMDA) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 11:06 AM EST - 3 months ago

Kamada Ltd. (KMDA) Q4 2024 Earnings Call Transcript

Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth

Mar 5, 2025, 7:05 AM EST - 3 months ago

Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth

Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025

Feb 26, 2025, 7:00 AM EST - 3 months ago

Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025

Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America

Jan 22, 2025, 7:00 AM EST - 5 months ago

Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America

Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 9:54 AM EST - 7 months ago

Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript

Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston

Sep 23, 2024, 7:00 AM EDT - 9 months ago

Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston

Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 1:45 PM EDT - 10 months ago

Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript

Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024

Aug 7, 2024, 7:00 AM EDT - 11 months ago

Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024

Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript

May 8, 2024, 11:55 AM EDT - 1 year ago

Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript

Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance

May 8, 2024, 7:00 AM EDT - 1 year ago

Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance

Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

May 1, 2024, 7:00 AM EDT - 1 year ago

Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 2:22 PM EST - 1 year ago

Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript

Kamada Issues 2024 CEO Letter to Shareholders

Mar 6, 2024, 7:05 AM EST - 1 year ago

Kamada Issues 2024 CEO Letter to Shareholders

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

Mar 6, 2024, 7:00 AM EST - 1 year ago

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024

Feb 28, 2024, 7:00 AM EST - 1 year ago

Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024

Kamada: Kedrion Deal Locks In Growth

Dec 8, 2023, 6:42 PM EST - 1 year ago

Kamada: Kedrion Deal Locks In Growth

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

Dec 7, 2023, 11:00 AM EST - 1 year ago

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

Dec 6, 2023, 7:00 AM EST - 1 year ago

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

Celebrating Seeking Alpha's New Analysts - November 2023 Edition

Dec 5, 2023, 12:00 PM EST - 1 year ago

Celebrating Seeking Alpha's New Analysts - November 2023 Edition

AGNC CROX DPZ FHI GRPN GRVY GTN

Kamada: Solid Specialty Plasma Play

Nov 21, 2023, 10:11 AM EST - 1 year ago

Kamada: Solid Specialty Plasma Play

Kamada Ltd. (KMDA) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 11:08 AM EST - 1 year ago

Kamada Ltd. (KMDA) Q3 2023 Earnings Call Transcript

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Nov 13, 2023, 7:00 AM EST - 1 year ago

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

Nov 8, 2023, 7:00 AM EST - 1 year ago

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

Kamada Provides Corporate Update on its Israel Operations

Oct 10, 2023, 7:37 AM EDT - 1 year ago

Kamada Provides Corporate Update on its Israel Operations

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

Oct 9, 2023, 8:53 AM EDT - 1 year ago

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

CGEN PLX TARO TEVA

Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

Aug 30, 2023, 7:00 AM EDT - 1 year ago

Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

Kamada Ltd. (KMDA) Q2 2023 Earnings Call Transcript

Aug 16, 2023, 3:53 PM EDT - 1 year ago

Kamada Ltd. (KMDA) Q2 2023 Earnings Call Transcript

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Aug 16, 2023, 7:00 AM EDT - 1 year ago

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023

Aug 9, 2023, 7:00 AM EDT - 2 years ago

Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023

Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.

Kamada: Deep Dive Following FIMI Placement, Rate Buy

Jun 21, 2023, 5:10 AM EDT - 2 years ago

Kamada: Deep Dive Following FIMI Placement, Rate Buy

Kamada Ltd. (KMDA) Q1 2023 Earnings Call Transcript

May 24, 2023, 1:21 PM EDT - 2 years ago

Kamada Ltd. (KMDA) Q1 2023 Earnings Call Transcript

Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

May 24, 2023, 7:10 AM EDT - 2 years ago

Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

May 24, 2023, 7:05 AM EDT - 2 years ago

Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds

May 24, 2023, 7:00 AM EDT - 2 years ago

Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds

Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023

May 17, 2023, 7:00 AM EDT - 2 years ago

Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023

Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland

May 16, 2023, 7:00 AM EDT - 2 years ago

Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland

Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company's Facility in Israel

May 3, 2023, 7:00 AM EDT - 2 years ago

Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company's Facility in Israel

Kamada Ltd. (KMDA) Q4 2022 Earnings Call Transcript

Mar 15, 2023, 4:07 PM EDT - 2 years ago

Kamada Ltd. (KMDA) Q4 2022 Earnings Call Transcript

Kamada Issues 2023 CEO Letter to Shareholders

Mar 15, 2023, 7:10 AM EDT - 2 years ago

Kamada Issues 2023 CEO Letter to Shareholders

Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

Mar 15, 2023, 7:00 AM EDT - 2 years ago

Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company's Facility in Israel

Jan 4, 2023, 7:00 AM EST - 2 years ago

Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company's Facility in Israel

Kamada Announces Planned Transition of Chief Financial Officer

Dec 19, 2022, 7:00 AM EST - 2 years ago

Kamada Announces Planned Transition of Chief Financial Officer

Kamada Ltd. (KMDA) Q3 2022 Earnings Call Transcript

Nov 22, 2022, 10:35 AM EST - 2 years ago

Kamada Ltd. (KMDA) Q3 2022 Earnings Call Transcript

Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance

Nov 22, 2022, 7:00 AM EST - 2 years ago

Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance

Kamada Awarded $22 Million Extension of Canadian Supply Tender

Oct 19, 2022, 7:00 AM EDT - 2 years ago

Kamada Awarded $22 Million Extension of Canadian Supply Tender

Kamada Ltd. (KMDA) CEO Amir London on Q2 2022 Results - Earnings Call Transcript

Aug 17, 2022, 1:58 PM EDT - 3 years ago

Kamada Ltd. (KMDA) CEO Amir London on Q2 2022 Results - Earnings Call Transcript

benzinga
benzinga Jun. 10 at 5:10 PM
Kamada Q1 Results: Double-Digit Growth, Company Reiterates Guidance As It Hits Multiple Milestones Including Plasma Business Expansion $KMDA https://www.benzinga.com/partner/earnings/25/06/45857873/kamada-q1-results-double-digit-growth-company-reiterates-guidance-as-it-hits-multiple-milestones
0 · Reply
benzinga
benzinga Jun. 5 at 6:37 PM
Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM $KMDA https://www.benzinga.com/partner/biotech/25/06/45790529/kamada-wants-to-do-more-for-organ-transplant-patients-increases-efforts-to-build-awareness-of-its
0 · Reply
Greenpa
Greenpa Jun. 1 at 2:03 AM
$KMDA Sold out of modest KMDA position. Hope to buy back later after analyst shave future earnings estimates to reflect that will be bear about 20 to 25 percent tax hit as NOLs used up. Next year’s eps seem likely to therefore be flat to down. Hope to buy back at $6 or less if works out as seems reasonable to expect.
1 · Reply
Greenpa
Greenpa May. 20 at 11:12 AM
$KMDA Current numbers do not reflect taxes. Quote fromQ1 call transcript: But as of now, we have yet -- we're still using NOLs, so we're not paying taxes. We expect to be in a taxable income and start paying taxes at the end of 2025 or beginning of 2026.
0 · Reply
Greenpa
Greenpa May. 16 at 9:15 PM
$KMDA The plasma centers only generate 10 to 15 percent gross margins. Not what I had anticipated. Out after earning maybe a few pennies.
0 · Reply
JarvisFlow
JarvisFlow May. 15 at 2:40 PM
Benchmark updates rating for Kamada ( $KMDA ) to Buy, target set at 15.
0 · Reply
Estimize
Estimize May. 15 at 10:00 AM
Wall St is expecting 0.08 EPS for $KMDA Q2 [Reporting 08/13 BMO] http://www.estimize.com/intro/kmda?chart=historical&metric_name=eps&utm_co
0 · Reply
Estimize
Estimize May. 14 at 10:18 PM
$KMDA reported 0.07 EPS and 44.02 revenue for Q1. http://www.estimize.com/intro/kmda?chart=historical&metric_name=eps&utm_content=KMDA&utm_
0 · Reply
Abcl2028
Abcl2028 May. 14 at 7:03 PM
$KMDA when are earnings released
0 · Reply
Sidoti
Sidoti May. 8 at 7:31 PM
New research today on @kamada $KMDA #sidotiresearch Read Note: https://buff.ly/IiU11i8 #investing #smallcap #microcap
0 · Reply
Abcl2028
Abcl2028 Apr. 25 at 9:07 AM
$KMDA 25% pre market drop. WTF
1 · Reply
benzinga
benzinga Apr. 21 at 5:12 PM
Kamada Expects Third Plasma Collection Site To Support Its Hyper-Immune Plasma Needs And Add Up To $10M In Annual Revenue At Full Capacity $KMDA https://www.benzinga.com/partner/biotech/25/04/44895325/kamada-expects-third-plasma-collection-site-to-support-its-hyper-immune-plasma-needs-and-add-up-t
0 · Reply
biotechNorway
biotechNorway Apr. 19 at 5:43 AM
$KMDA has sold off with the broader market despite being largely recession-proof. Their core product is a rabies vaccine—administered after animal bites—placing them in a niche oligopoly with only one other global competitor. Due to secured purchasing contracts, the company has effectively locked in double-digit growth over the next three years. Currently, it trades at an EV/EBITDA of just 7, with $60M in cash on hand managed by the best private equity in the Middle East.
1 · Reply
TOOL88
TOOL88 Apr. 17 at 2:36 PM
$KMDA Today the stock closed in Israel at $6.66 on fairly large volume. Here the MMS keeps the price about 3% lower, why?
1 · Reply
Biotekman
Biotekman Apr. 17 at 12:54 AM
$KMDA The definition of an oxymoron: - Slide 9: 11.5 M$ stupidly paid to shareholders. - Slide 10: an ambitious roadmap for double-digit growth. What's wrong with the management? Do they understand that they need as much cash as possible to grow?
1 · Reply
benzinga
benzinga Apr. 15 at 1:58 PM
Kamada Is Bringing Relief To Those With Rare And Serious Conditions $KMDA https://www.benzinga.com/partner/biotech/25/04/44810773/kamada-is-bringing-relief-to-those-with-rare-and-serious-conditions
0 · Reply
Biotekman
Biotekman Apr. 14 at 11:08 PM
$KMDA this stock looks interesting, but I don't understand the management: why did they pay a special dividend??? For a growth company? Around 10 M$ lost, this money would have been precious to acquire new plasma collection centers. I really don't understand.
1 · Reply
FinJay
FinJay Apr. 5 at 3:47 AM
$KMDA https://youtu.be/ZgdQySZotaQ
0 · Reply
SuperBusa
SuperBusa Mar. 31 at 5:06 PM
$KMDA
0 · Reply
Sidoti
Sidoti Mar. 28 at 3:16 PM
New research today on @kamada $KMDA #sidotiresearch Read Note: https://buff.ly/ExBAW6w #investing #smallcap #microcap
0 · Reply
Greenpa
Greenpa Mar. 27 at 12:54 AM
$KMDA Do any of the biopharma experts considered what KMDA might fetch if it sold the AATD business outright with or without retention of a royalty stream.
0 · Reply
Greenpa
Greenpa Mar. 26 at 10:17 PM
$KMDA I expect favorable futility anaolagef this year which would then open up partnership potential. Only 52 million shares outstanding and should have lead position in $1.5 billion AATD market. Given FDA approval of reduced trial size and ability of inhaler to be directly introduced into the lungs with 12 percent of IV medication and at home administration, the odds seem strong. Time will tell but this opportunity seems like it is not being valued.
0 · Reply